Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 126
---
 our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product
candidates. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions
are available.

In some instances, we submit
patent applications directly to the USPTO as provisional patent applications. Corresponding non-provisional patent applications must be
filed not later than 12 months after the provisional application filing date. While we intend to timely file non-provisional patent applications
relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of
patents that provide us with any competitive advantage.

We will file U.S. non-provisional
applications and Patent Cooperation Treaty (“PCT”) applications that claim the benefit of the priority date of earlier filed
provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority
date of the provisional patent application, and to designate all of the PCT member states in which national phase patent applications
can later be pursued based on the international patent application filed under the PCT. The PCT search authority performs a patentability
search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications
in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant
to seek protection in any of the member states through national-phase patent applications. At the end of the period of 30 months from
the first priority date of the provisional patent application, separate national phase patent applications can be pursued in any of the
PCT member states either by direct national filing, or in some cases, by filing through a regional patent organization, such as the European
Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications,
and enables substantial savings where applications are abandoned within the first thirty months of filing.

For all patent applications,
we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We continuously
reassess the number and type of patent applications, as well as the scope of our patent claims to pursue coverage and value for our processes
and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet
our